Evidence map›Paper›PMID 29178941›Full record

Observational studyScandinavian journal of trauma, resuscitation and emergency medicine2017

S100A8/A9 and sRAGE kinetic after polytrauma; an explorative observational study.

Philippe Joly, John C Marshall, Philippe A Tessier, Chantal Massé, Nathalie Page, Anne Julie Frenette, François Khazoom, Soazig Le Guillan, Yves Berthiaume, Emmanuel Charbonney

Abstract readObservational Study
In one paragraph

Observational study in Scandinavian journal of trauma, resuscitation and emergency medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Philippe JolyFaculté de Médecine, Université de Montréal, Montréal, Canada.
John C MarshallSt. Michael's Hospital and the Keenan Research Centre for Biomedical Science, University of Toronto, Toronto, Canada.
Philippe A TessierAxe de recherche sur les maladies infectieuses et l'immunitaires, Centre de recherche du CHU de Québec-Université Laval, and Département de microbiologie-infectiologie et immunologie, Faculté de Médecine, Université Laval, Québec, Canada.
Chantal MasséInstitut de recherches cliniques de Montréal, Université de Montréal, Montréal, Canada.
Nathalie PageAxe de recherche sur les maladies infectieuses et l'immunitaires, Centre de recherche du CHU de Québec-Université Laval, and Département de microbiologie-infectiologie et immunologie, Faculté de Médecine, Université Laval, Québec, Canada.
Anne Julie FrenetteHôpital du Sacré-Coeur de Montréal, CIUSSS-NIM, Montréal, Canada.
François KhazoomFaculté de Médecine, Université de Montréal, Montréal, Canada.
Soazig Le GuillanHôpital du Sacré-Coeur de Montréal, CIUSSS-NIM, Montréal, Canada.
Yves BerthiaumeInstitut de recherches cliniques de Montréal, Université de Montréal, Montréal, Canada.
Emmanuel CharbonneyInstitut de recherches cliniques de Montréal, Université de Montréal, Montréal, Canada. emmanuel.charbonney@umontreal.ca.ORCID http://orcid.org/0000-0002-0409-3334

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFollowing tissue injury after trauma, the activation of innate immune pathways results in systemic inflammation, organ failure and an increased risk of infections. The objective of this study was to characterize the kinetics of the S100A8/S100A9 complex, a new-recognized alarmin, as well as its soluble receptor sRAGE, over time after trauma as potential early biomarkers of the risk of organ damage.

methodsWe collected comprehensive data from consenting patients admitted to an ICU following severe trauma. The blood samples were taken at Day 0 (admission), Day1, 3 and 5 S100A8/A9 and sRAGE were measured by ELISA. Biomarkers levels were reported as median (IQR).

resultsThirty-eight patients sustaining in majority a blunt trauma (89%) with a median ISS of 39 were included. In this cohort, the S100A8/A9 complex increased significantly over time (p = 0.001), but its levels increment over time (D0 to D5) was significantly smaller in patients developing infection (7.6 vs 40.1 mcg/mL, p = 0.011). The circulating level of sRAGE circulating levels decreased over time (p < 0.0001) and was higher in patients who remained in shock on day 3 (550 vs 918 pg/mL; p = 0.02) or 5 (498 vs 644 pg/mL; p = 0.045). Admission sRAGE levels were significantly higher in non-survivors (1694 vs 745 pg/mL; p = 0.015) and was higher in patients developing renal failure (1143 vs 696 pg/mL, p = 0.011). DISCUSSION: Our findings reveal an interesting association between the biomarker S100A8/9 least increase over time and the presence of infectious complication after trauma. We describe that the sRAGE decline over time is in relation with shock and markers of ischemic injury. We also confirm the association of sRAGE levels measured at admission with mortality and the development of renal failure.

conclusionsThis work illustrates the importance of following the circulating level of biomarker overtime. The utilization of S1008/9 as a tool to stratify infection risk and trigger early interventions need to be validated prospectively.

Indexed as

AdultBiomarkersCalgranulin ACalgranulin BCohort StudiesEnzyme-Linked Immunosorbent AssayFemaleHumansInflammationMaleMiddle AgedMultiple Organ FailureMultiple TraumaReceptor for Advanced Glycation End ProductsRiskTime FactorsBiomarkersCalgranulin ACalgranulin BReceptor for Advanced Glycation End ProductsCalgranulinesInfectionInflammationOrgan failureS100sRAGETrauma

Identifiers

PMID29178941
PMCPMC5702249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.